研究者詳細 - 藤原　俊義

MISC - 藤原　俊義

分割表示 922 件中 481 - 500 件目／全件表示 >>

StageIII大腸癌根治術後の再発予測におけるMGMTプロモーター領域のメチル化解析の有用性

母里淑子, 永坂岳司, 竹原裕子, 吉田一博, 重安邦俊, 楳田祐三, 田澤大, 貞森裕, 藤原俊義

日本消化器外科学会総会 68回 O - 39 2013年7月

温阻血再灌流+70%肝切除におけるHMGB1の動態解析と制御

杉原正大, 貞森裕, 佐藤太祐, 吉田龍一, 楳田祐三, 篠浦先, 田澤大, 永坂岳司, 八木孝仁, 藤原俊義

日本消化器外科学会総会 68回 RS - 54 2013年7月

A novel synergistic effect of iron depletion on antiangiogenic cancer therapy．

Ohara T, Noma K, Urano S, Watanabe S, Nishitani S, Tomono Y, Kimura F, Kagawa S, Shirakawa Y, Fujiwara T

Int J Cancer 132 ( 11 ) 2705 - 2713 2013年6月

Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy．

Nobuoka D, Yoshikawa T, Fujiwara T, Nakatsura T

Hum Vaccin Immunother 9 ( 6 ) 1234 - 1236 2013年6月

妊婦の虫垂炎 (特集必見! アッペのすべて : 疫学・診断から単孔式内視鏡手術まで) -- (特殊な虫垂炎手術)

近藤喜太, 藤原俊義

外科 75 ( 6 ) 622 - 625 2013年6月

CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy．

Satoh D, Yagi T, Nagasaka T, Shinoura S, Umeda Y, Yoshida R, Utsumi M, Tanaka T, Sadamori H, Fujiwara T

World J Hepatol 5 ( 4 ) 189 - 195 2013年4月

Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination

Kunitoshi Shigeyasu, Shunsuke Kagawa, Futoshi Uno, Masahiko Nishizaki, Hiroyuki Kishimoto, Akira Gochi, Toshikazu Kimura, Takaomi Takahata, Yasuyuki Nonaka, Motoki Ninomiya, Toshiyoshi Fujiwara

Cancer Chemotherapy and Pharmacology 71 ( 4 ) 937 - 943 2013年4月

記述言語：英語

Purpose: Peritoneal dissemination is the most frequent and life-threatening mode of metastasis and recurrence in patients with gastric cancer. A multicenter phase II study was designed to evaluate the efficacy and tolerability of S-1 and docetaxel combination chemotherapy regimen for the treatment of advanced or recurrent gastric cancer patients with peritoneal dissemination. Methods: Nineteen patients with histologically confirmed unresectable or recurrent gastric cancer with peritoneal dissemination were enrolled. Oral S-1 at 80 mg/m2/day was administered twice daily for 2 weeks, followed by 1 drug-free week. Docetaxel infusion at 40 mg/m2 was performed on day 1, simultaneous with S-1 administration. The primary endpoints were overall survival (OS) and time to progression (TTP). The secondary endpoints were the response rates and safety status. Results: Patients received a median of 4 cycles of the S-1 and docetaxel regimen (range 1-43). The disease control rate was 73.7 % (14/19). Median overall survival was 459 days (15.3 months), while median time to progression was 212 days (7.1 months). Neutropenia was the most common type of toxicity (n = 7, 36.8 %). Conclusions: Combination chemotherapy with S-1 and docetaxel is a tolerable and effective treatment for advanced or recurrent gastric cancer patients with peritoneal dissemination. © 2013 Springer-Verlag Berlin Heidelberg.

DOI： 10.1007/s00280-013-2086-0

Scopus

PubMed

researchmap

Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy．

Nobuoka D, Yoshikawa T, Takahashi M, Iwama T, Horie K, Shimomura M, Suzuki S, Sakemura N, Nakatsugawa M, Sadamori H, Yagi T, Fujiwara T, Nakatsura T

Cancer Immunol Immunother 62 ( 4 ) 639 - 652 2013年4月